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Antidepressant mechanism of
ketamine: perspective from
preclinical studies
Lisa Scheuing, Chi-Tso Chiu, Hsiao-Mei Liao and De-Maw Chuang*
Molecular Neurobiology Section, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA
A debilitating mental disorder, major depressive disorder is a leading cause of global
disease burden. Existing antidepressant drugs are not adequate for the majority of
depressed patients, and large clinical studies have demonstrated their limited efficacy
and slow response onset. Growing evidence of low-dose ketamine’s rapid and potent
antidepressant effects offers strong potential for future antidepressant agents. However,
ketamine has considerable drawbacks such as its abuse potential, psychomimetic
effects, and increased oxidative stress in the brain, thus limiting its widespread clinical
use. To develop superior antidepressant drugs, it is crucial to better understand
ketamine’s antidepressant mechanism of action. Recent preclinical studies indicate that
ketamine’s antidepressant mechanism involves mammalian target of rapamycin pathway
activation and subsequent synaptogenesis in the prefrontal cortex, as well as glycogen
synthase kinase-3 beta (GSK-3β) inactivation. Adjunct GSK-3β inhibitors, such as lithium,
can enhance ketamine’s efficacy by augmenting and prolonging its antidepressant
effects. Given the potential for depressive relapses, lithium in addition to ketamine is
a promising solution for this clinical issue.
Keywords: ketamine, NMDA antagonist, major depressive disorder, lithium, GSK-3 inhibitor, mTOR, therapeutic
potential
Introduction
A devastating mental disorder, major depressive disorder (MDD) is a leading global disease burden
and is currently the eleventh highest contributor to global disability-adjusted life years (Murray
et al., 2012). In the United States alone, MDD remains the second highest contributor to years
lived with disability, and recently rose to the fifth leading contributor to disability-adjusted life
years according to epidemiological studies from 1990 to 2010 (Collaborators, 2013). The mental
health community is largely in agreement that current antidepressant drugs are not adequate
due to the long treatment time course required to reach full efficacy (weeks to months), and
their limited response in treatment-resistant patients (Insel and Wang, 2009). Many depressed
patients, especially those who are at risk for suicide, require an effective, fast-acting antidepressant.
Abbreviations: 4E-BP1, 4E-binding protein 1; Akt/PKB, protein kinase B; AMPA, α-amino-3-hydroxy-5-methylisoxazole-
4-propionic acid; Arc, activity-regulated cytoskeletal-associated protein; BDNF, brain-derived neurotrophic factor; eEF2K,
eukaryotic elongation factor 2 kinase; eEF2, eukaryotic elongation factor 2; eIF4E, eukaryotic initiation factor 4E; ERK1/2,
extracellular signal-regulated kinase; FST, forced swim test; GSK-3, glycogen synthase kinase-3; MDD, major depressive
disorder; mPFC, medial prefrontal cortex; mTOR, mammalian target of rapamycin; NMDA, N-methyl-D-aspartate; p70S6K,
p70 ribosomal protein S6 kinase; PFC, prefrontal cortex; PSD95, postsynaptic density protein 95; ROS, reactive oxygen
species; TrkB, tropomyosin receptor kinase B.
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Ketamine is a non-competitive glutamate N-methyl-D-aspartate
(NMDA) receptor antagonist, and has been widely used as
an anesthetic agent (Sanacora and Schatzberg, 2015). During
the past 15 years, numerous clinical studies have provided
strong evidence that a single sub-anesthetic dose of ketamine
rapidly and robustly alleviates depressive symptoms in MDD
patients. Additionally, animal models of depression have
allowed researchers to unravel ketamine’s unique antidepressant
mechanism of action. In this review we will discuss the
clinical usage of ketamine, highlight seminal papers that
elucidate ketamine’s antidepressant mechanism, and propose
future directions for this promising developing field.
Clinical Usage of Ketamine as an
Antidepressant
It is now widely accepted that ketamine is an effective and
fast-acting antidepressant, proven to be beneficial for a variety
of depressed patients. The first clinical study to assess the
antidepressant effects of ketamine at a dose of 0.5mg/kg,
given intravenously over 40min, significantly reduced depressive
symptoms in MDD patients within 24 h, compared with saline
placebo (Berman et al., 2000). However, ketamine-treated
patients experienced dissociative side effects during the first
2 h post-infusion. A subsequent trial demonstrated ketamine’s
effectiveness in treatment-resistant MDD, which is defined as
inadequate response to more than two antidepressants (Zarate
et al., 2006). However, a single ketamine infusion was not
long-lasting, with 35% of patients maintaining a significant
antidepressant response for up to 1 week. While the majority
of clinical studies reported the effects of a single ketamine
administration, repeated ketamine therapy of six infusions over
12 days was safe and well tolerated in treatment-resistant MDD
patients (Aan Het Rot et al., 2010). Further evidence of successful
repeated ketamine therapy reported an overall response rate of
70.8% for treatment-resistant patients, with a median depressive
relapse time of 18 days (Murrough et al., 2013b). Compared
with an average of 7 days until non-significant response or
depressive relapse, 18 days until depressive relapse demonstrates
strong improvement. To compensate for the initial dissociative
symptoms of ketamine, a large double-blind study used a
psychoactive placebo, midazolam, to compare antidepressant
effectiveness and described response rates of 64% for ketamine
but only 28% for midazolam (Murrough et al., 2013a). While
there is no perfect placebo for ketamine, the use of midazolam
is a better substitute than saline because it blinds patients to
treatment.
In sharp contrast to the slow onset of existing antidepressants,
ketamine’s fast-acting effects provide relief for MDD patients
at risk for suicide. For example, ketamine infusions rapidly
decreased explicit suicidal ideation in MDD patients within 24 h
(Price et al., 2009), even when compared to midazolam (Price
et al., 2014). In addition to MDD, ketamine is an effective
antidepressant for bipolar-depressed patients as demonstrated
by double-blind, saline placebo-controlled studies, in which
patients had response rates of 70% or greater to ketamine
(Diazgranados et al., 2010; Zarate et al., 2012b). Ketamine has
also shown promise to decrease symptoms in both obsessive-
compulsive disorder (Rodriguez et al., 2013) and post-traumatic
stress disorder (Feder et al., 2014) patients. However, further
double-blind trials with appropriate placebos are required to
assess ketamine’s long-term effects, in addition to its potential to
treat psychiatric disorders besides MDD.
Ketamine’s Antidepressant Mechanism of
Action
It was first reported that MK-801, a non-competitive NMDA
receptor antagonist, exhibited antidepressant-like actions
in mice (Trullas and Skolnick, 1990). A later preclinical
study demonstrated that ketamine injected male rats showed
significantly less immobility during the forced swim test (FST)
compared with saline controls, and inferred that the animals
exhibited less behavioral despair than controls (Yilmaz et al.,
2002). In addition, ketamine-injected male rats had reduced
immobility time in the FST and had increased hippocampal
brain-derived neurotrophic factor (BDNF) protein levels in
comparison to untreated rats, suggesting involvement of the
tropomyosin receptor kinase B (TrkB) signaling pathway (Garcia
et al., 2008). Mice that underwent the learned helplessness
paradigm were also responsive to ketamine treatment as
demonstrated by decreased immobility times in the FST, and
pre-treatment with an α-amino-3-hydroxy-5-methylisoxazole-4-
propionic acid (AMPA) receptor antagonist NBQX attenuated
the antidepressant-like behavior induced by ketamine, suggesting
that pre-synaptic NMDA receptor blockade and post-synaptic
AMPA receptor activation and upregulation is necessary for
ketamine’s antidepressant effects (Maeng et al., 2008).
In a pivotal study, researchers demonstrated that ketamine
rapidly and transiently activated the mammalian target of
rapamycin (mTOR) signaling pathway in the medial prefrontal
cortex (mPFC) of male rats (Li et al., 2010). Evidence of
mTOR activation was supported by increased phosphorylation of
upstream proteins including extracellular signal-regulated kinase
(ERK; forms 1 and 2) and protein kinase B (PKB/Akt), and
downstream proteins p70 ribosomal protein S6 kinase (p70S6K)
and translation repressor protein 4E-binding protein 1 (4E-BP1).
The phosphorylation increases for the respective active protein
forms were dose-dependent, with peak activation occurring at
low ketamine doses (5–10mg/kg), and were transient, lasting up
to 2 h. Stimulation of p70S6K increases the synthesis of ribosomal
unit S6, and overall increases protein translation (Fenton and
Gout, 2011), whereas the hyper-phosphorylation of 4E-BP1 dis-
inhibits protein translation by decreasing eukaryotic initiation
factor 4E (eIF4E) activity, allowing for the recruitment of
translationmachinery tomRNA (Gingras et al., 2001). Ketamine-
induced mTOR activation also significantly increased mRNA and
protein levels of activity-regulated cytoskeletal-associated protein
(Arc), synapsin I, postsynaptic density protein 95 (PSD95),
and GluR1 (an AMPA receptor subunit), all proteins critically
involved in the formation, maturation and function of new
spine synapses (Li et al., 2010). In support of behavioral despair
model findings, ketamine treatment reversed behavioral and
synaptic spine deficits caused by chronic unpredictable stress,
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which induced anhedonia- and anxiety-like behaviors; ketamine
alleviated decreased synaptic density protein levels of synapsin I,
PSD95, and GluR1within the rat mPFC (Li et al., 2011).
Preclinical findings of significantly lower synaptic spine
density proteins in animal depression models have been
reinforced by post-mortem studies of MDD subjects who had
reduced levels of PSD95 (Feyissa et al., 2009), as well as
significantly lower protein levels of mTOR and p70S6K (Jernigan
et al., 2011), in the PFC compared to sex- and age-matched
controls. Unlike other widely prescribed antidepressants such as
imipramine or fluoxetine, activation of the mTOR pathway and
its associated increase in synaptic spine density within the mPFC
is one unique mechanism underlying ketamine’s antidepressant-
like effects (Park et al., 2014). It is important to note that there
are two complexes associated with mTOR, complex 1 (mTORC1)
which requires regulatory-associated protein of mTOR (Kim
et al., 2002), and complex 2 (mTORC2) which contains
rapamycin-independent companion of mTOR (Sarbassov et al.,
2004). While mTORC2 could potentially regulate ketamine’s
antidepressant effects, the fact that rapamycin pre-treatment
prevents the antidepressant actions of ketamine, given that
rapamycin has a greater affinity for mTORC1 (Sarbassov et al.,
2005), strongly suggests that mTORC1 is the primary target
(Li et al., 2010, 2011). Future, studies should use specific
mTOR complex inhibitors to determine which mTOR complex
is necessary for the different molecular events of ketamine’s
antidepressant mechanism.
Besides mTOR activation, another important process required
for ketamine’s antidepressant effects is the production and
release of BDNF, a neurotrophic factor essential for neuron
development, survival, and synaptic plasticity (Autry and
Monteggia, 2012). One mechanism explains that NMDA
receptor blockade leads to downstream inhibition of eukaryotic
elongation factor 2 kinase (eEF2K) by p70S6K, thus decreasing
the phosphorylation of eEF2K’s target protein, eEF2, and
overall de-suppressing protein translation machinery, resulting
in enhanced BDNF expression within the hippocampus (Autry
et al., 2011). Unlike the uniqueness of the rapid and transient
mTOR pathway activation, enhanced BDNF expression is a
common event for both ketamine and classical antidepressants
(Monteggia and Zarate, 2015). Increased BDNF production and
release is critical for ketamine’s rapid mechanism of action,
demonstrated by the lack of antidepressant-like response to
ketamine in BDNF-conditional knockout mutant mice (Autry
et al., 2011), or in mice infused with a neutralizing BDNF
antibody in the extracellular space of the mPFC (Lepack et al.,
2014).
Another mechanism proposes that ketamine causes increased
BDNF signaling via post-synaptic AMPA receptor stimulation,
depolarizing the cell, activating L-type voltage-dependent
calcium channels, thus allowing for calcium influx and resultant
activity-dependent exocytosis of BDNF (Lepack et al., 2014).
BDNF then activates the TrkB signaling pathway, causing
phosphorylation and activation of downstream effector proteins
ERK1/2 and Akt through the MEK and PI3K signaling pathways,
respectively. BDNF upregulation due to ketamine administration
also leads to acute changes in synaptic plasticity (increased
surface expression of AMPA receptors) within the hippocampus
(Nosyreva et al., 2013; see Kavalali and Monteggia, 2012 for
details about ketamine and synaptic plasticity).
Further, support of BDNF’s involvement stems from the
decreased antidepressant-like effectiveness of ketamine in
genetically engineered mice carrying at least one allele with
methionine substituted for valine of the BDNF Val66Met
polymorphism (Liu et al., 2012), which has also been confirmed
in a small sample of human MDD patients (Laje et al., 2012).
Having two methionine alleles (met/met) of the Val66Met
polymorphism reduces BDNF production and release, and
cognitively is correlated with poorer episodic memory (Egan
et al., 2003). It has been suggested that because 25% of the general
population is estimated to have the Val66Met polymorphism
(Petryshen et al., 2010); this may potentially explain why
approximately one third of MDD patients are non-responders to
ketamine. However, it is likely that a more complex combination
of factors is why some MDD patients are unresponsive to
ketamine treatment.
Another significant protein called glycogen synthase kinase-3
(GSK-3), a master switch serine-threonine kinase implicated in
psychiatric disorders such as MDD and bipolar disorder (Beurel
et al., 2015), undergoes necessary inhibition for ketamine’s
rapid antidepressant effects. Researchers used a knock-in mouse
model rendering both the alpha and beta isoforms of GSK-3
maximally active, by eliminating the inhibitory phosphorylation
sites of serine-21 and -9 for GSK-3α and GSK-3β, respectively
(Beurel et al., 2011). When GSK-3 could not be inhibited, the
antidepressant-like effects of ketamine were not observed in
the learned helplessness paradigm. Thus, GSK-3 inhibition is
also necessary for ketamine’s rapid antidepressant-like effects.
Building upon the requirement of decreased GSK-3 activity, two
separate preclinical studies have demonstrated that lithium, a
GSK-3 inhibitor, combined with low-dose ketamine potentiated
and prolonged the molecular and behavioral effects of ketamine
(Liu et al., 2013; Chiu et al., 2014), see Figure 1 for a schematic.
These two studies will be discussed in depth in the following
section.
Issues with Ketamine Treatment and
Possible Solutions
Ketamine infusions have proven to be beneficial for patients
with treatment-resistant depression, however, ketamine also
temporarily causes dissociative symptoms, has risk for abuse,
and has been shown preclinically to increase oxidative stress
in the rat brain (Zuo et al., 2007). In addition, it is evident
from both clinical and preclinical studies that the antidepressant
effects induced by a single ketamine administration usually last 1
week. Therefore, although ketamine rapidly reduces depressive
symptoms, repeated infusions are necessary to maintain its
effects. However, repeated ketamine administrations can cause a
variety of side effects in humans such as cognitive impairments
and psychomimetic symptoms (Krystal et al., 2005). Moreover,
administration of sub-anesthetic doses of ketamine in animals
has been used as a pharmacological model of schizophrenia
(Gunduz-Bruce, 2009) and is known to induce schizophrenia-like
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FIGURE 1 | Putative signaling pathways involved in ketamine’s
antidepressant effects and the potentiation by lithium. Ketamine
blocks pre-synaptic NMDAR signaling, resulting in increased glutamate
release. Enhanced glutamate signaling activates post-synaptic AMPA
receptors, and the resultant cell depolarization stimulates
voltage-dependent calcium channels (VDCC), leading to calcium influx
and BDNF exocytosis. BDNF release activates TrkB receptors and
downstream signaling pathways, PI3K-Akt and MEK-Erk1/2. Both
pathways activate mTOR complex 1 through phosphorylation. The
activity of mTOR can be potentiated by lithium through Akt activation
and GSK-3 inhibition. mTOR then phosphorylates and activates p70S6K,
which inhibits eEF2K, halting the phosphorylation of eEF2, effectively
inhibiting eEF2. In parallel, mTOR hyperphosphorylates 4E-BP1, reducing
its interaction with eIF4E. Together, decreased eEF2 phosphorylation and
the release of eIF4E from 4E-BP1 disinhibit protein translation, producing
more synaptic proteins such as GluR1, PSD95, Arc, and synapsin I, as
well as BDNF. This facilitates increased dendritic spine density and
synaptogenesis in the prefrontal cortex and hippocampus, and leads to
antidepressant-like behavior in rodents. Lines with arrows represent
stimulatory connections; lines with flattened ends represent inhibitory
connections. Dashed lines represent pathways with reduced activity as a
result of ketamine or lithium treatment.
behaviors in humans (Krystal et al., 2003). For the reasons above,
ketamine is not widely used for the treatment of MDD.
One proposed solution involves ketamine treatment in
addition to the mood stabilizer lithium, and preclinically it
has been shown to potentiate the behavioral and molecular
antidepressant-like effects of ketamine in rodent models of
depression (Liu et al., 2013; Chiu et al., 2014). Lithium is
known to directly inhibit both isoforms of GSK-3 (Freland
and Beaulieu, 2012), and can also indirectly inactivate GSK-3
through Akt, which phosphorylates GSK-3’s negative regulatory
site (Chalecka-Franaszek and Chuang, 1999). Both the kinases
Akt and p70S6K, which are involved in the mTOR pathway,
can phosphorylate and and inhibit GSK-3 (Sutherland et al.,
1993; Cross et al., 1995). In mouse kidney tubule cells, lithium
treatment activated mTORC1 (Gao et al., 2013), however,
less is known about lithium’s interactions with mTORC2.
Additionally, lithium can increase BDNF exon IV and promoter
IV mRNA levels (Yasuda et al., 2009), suggesting that lithium
may have a role in synaptogenesis (Zunszain et al., 2013).
Indeed, adjunct lithium potentiated the frequency of serotonin-
or hypocretin-induced excitatory postsynaptic currents in mPFC
pyramidal cells, enhanced dendritic spine density and spine
head diameter of mPFC layer V pyramidal neurons, increased
mTOR and decreased GSK-3β signaling in the mPFC, and
sustained the decreased FST immobility time of rats treated
with a single low-dose ketamine injection (Liu et al., 2013).
Long-term treatment of stressed mice with lithium in the
drinking water potentiated and prolonged ketamine’s molecular
and behavioral antidepressant-like effects (Chiu et al., 2014).
Specifically, post-ketamine lithium treatment demonstrated that
lithium (1200 mg/L) prolonged antidepressant-like behavior and
increased mPFC dendritic spine density of a single ketamine
injection (50mg/kg), up to 2 weeks. Pre-ketamine treatment
with low-dose lithium (600 mg/L) for 2 weeks with a minimal
dose of ketamine (2.5mg/kg) acted synergistically to produce
antidepressant-like behavior and molecular changes, at dosages
that did not produce significant differences when administered
separately.
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Increased oxidative stress has been observed in psychiatric
disorders such as MDD, schizophrenia and bipolar disorder,
and has been suggested as a common underlying pathogenic
mechanism (Ng et al., 2008). Significantly, increased plasma
levels of malondialdehyde, a product of lipid peroxidation,
glutathione peroxidase, an enzyme that reduces lipid
hydroperoxides and free hydrogen peroxides, and other markers
of oxidative stress were found in MDD patients compared
to healthy controls (Sarandol et al., 2007). The increased
levels of oxidative stress markers confer increased cellular
susceptibility to oxidative damage from reactive oxygen species
(ROS). While low-dose ketamine produces rapid and effective
antidepressant results, one concern of ketamine treatment is its
propensity to increase brain levels of harmful ROS. For instance,
administration of sub-anesthetic doses of ketamine produced
increased hydroxyl radical production and lipid peroxidation,
and altered the activity of antioxidant enzymes, superoxide
dismutase and catalase, in the rodent brain (Zuo et al., 2007;
De Oliveira et al., 2009; Da Silva et al., 2010). In a chronic
stress model, mice that also received a single ketamine injection
(50mg/kg) had significantly higher levels of lipid peroxidation,
catalase activity, and oxidized glutathione, however, stressed
animals that received lithium adjunct (1200mg/L in drinking
water) to ketamine treatment suppressed the high levels of
oxidative stress in the PFC, hippocampus, and striatum (Chiu
et al., 2014). Pre-ketamine lithium treatment neuroprotectively
sustained lower levels of ROS, comparable with untreated
stressed mice, highlighting the anti-oxidant properties of
lithium.
Taken together, given the inevitable relapse of depressive
symptoms and suicidal ideation, the preclinical results described
above indicate that the GSK-3 inhibitor lithium, the mood
stabilizer with strong anti-suicidal properties (Cipriani et al.,
2005), may be a solution to this clinical issue, and provide
a strong justification for the adjunctive use of lithium with
ketamine in the treatment of depression. These results are
consistent with a recent clinical observation that lithium-
treated patients with bipolar disorder expressed greater
anti-anhedonic responses to ketamine (Lally et al., 2014).
In fact, several clinical trials are underway to assess the
therapeutic benefits of lithium when given in conjunction with
ketamine.
Conclusion and Future Directions
Ketamine rapidly and robustly improves depressive symptoms
and suicidal ideation of MDD subjects, and ameliorates
behavioral andmolecular deficits in animal models of depression.
While preclinical experiments easily explore molecular targets
of ketamine, the dosages used in preclinical studies have varied
making it difficult to directly compare results from various
studies. One explanation for the varying dosage requirements is
that rodent strains respond to or metabolize ketamine differently.
Thus, future preclinical studies should aim to understand why
there are variations in ketamine dosage and response. Also
notably, it has not been universally replicated that a single dose of
ketamine produced sustained anti-depressant-like effects (Popik
et al., 2008; Bechtholt-Gompf et al., 2011). The reason for this
discrepancy deserves further investigations.
The working model shown in Figure 1 is to illustrate the
possible mechanisms underlying the rapid antidepressant effects
of ketamine and the potentiation of this efficacy by lithium.
However, several issues need to be clarified. For example,
given that ketamine seems to have similar affinity for pre-
and post-synaptic NMDA receptors, what is the role of post-
synaptic NMDA receptor inhibition in mediating ketamine’s
antidepressant effects? Lithium has been reported to be a blocker
of NMDA receptors as shown by inhibition of receptor-mediated
calcium influx in primary brain neurons (Hashimoto et al.,
2002, 2003) and blockade of receptor-mediated activation of
cytosolic phospholipase A2 in the rat brain (Rapoport, 2014).
Could it be that the potentiation by lithium is contributed by
further inhibition of NMDA receptor activity? Some of the
pharmacologic effects of ketamine appear related to circulating
metabolites of this drug (Zarate et al., 2012a). Future studies
of the mechanisms of action of ketamine metabolites are also
warranted.
Another issue with preclinical studies is the unequal numbers
of male and female animals, resulting in less molecular and
behavioral data regarding the female animal response to a
sub-anesthetic dosage of ketamine. Many of the preclinical
experiments only used male animals, but recent findings indicate
that sex differences are present in the antidepressant effects
of ketamine. For example, female Sprague-Dawley rats were
more sensitive than males to the antidepressant effects of
ketamine, responding to a lower dose (2.5mg/kg), which was
shown to be mediated by the gonadal hormones estrogen
and progesterone (Carrier and Kabbaj, 2013). Therefore, future
ketamine antidepressant research should include analysis of
female animals, for enhanced research reproducibility, and for
more accurate translation to clinical populations.
As an initial goal, we suggest that researchers study treatments,
such as low-dose lithium, which can prolong ketamine’s
antidepressant effects greater than 1 week, or other agents
which can cause rapid antidepressant actions with fewer side
effects than ketamine, such as GLYX-13, an NMDA receptor
glycine-site functional partial agonist (Burgdorf et al., 2013).
However, more large-scale clinical and preclinical studies are
needed to assess the safety and feasibility of ketamine and lithium
adjunct for widespread clinical use. Lastly, it will be critical
to determine all the specific synaptic mechanisms underlying
ketamine’s antidepressant actions to create better treatments for
those suffering from depression.
Acknowledgments
This work was supported by the Intramural Research Program
of the National Institute of Mental Health, National Institutes
of Health (IRP-NIMH-NIH). The authors thank Peter Leeds of
the NIMH, NIH for his excellent editorial assistance. This work
was written as part of the authors’ official duties as Government
employees (affiliated with Annual Report MH002468). The views
expressed in this article do not necessarily represent the views of
the NIMH, NIH, HHS, nor the United States Government.
Frontiers in Neuroscience | www.frontiersin.org 5 July 2015 | Volume 9 | Article 249
Scheuing et al. Ketamine’s antidepressant mechanism of action
References
Aan Het Rot, M., Collins, K. A., Murrough, J. W., Perez, A. M., Reich, D. L.,
Charney, D. S., et al. (2010). Safety and efficacy of repeated-dose intravenous
ketamine for treatment-resistant depression. Biol. Psychiatry 67, 139–145. doi:
10.1016/j.biopsych.2009.08.038
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P. F.,
et al. (2011). NMDA receptor blockade at rest triggers rapid behavioural
antidepressant responses. Nature 475, 91–95. doi: 10.1038/nature10130
Autry, A. E., and Monteggia, L. M. (2012). Brain-derived neurotrophic
factor and neuropsychiatric disorders. Pharmacol. Rev. 64, 238–258. doi:
10.1124/pr.111.005108
Bechtholt-Gompf, A. J., Smith, K. L., John, C. S., Kang, H. H., Carlezon, W. A.
Jr., Cohen, B. M., et al. (2011). CD-1 and Balb/cJ mice do not show enduring
antidepressant-like effects of ketamine in tests of acute antidepressant efficacy.
Psychopharmacol. (Berl). 215, 689–695. doi: 10.1007/s00213-011-2169-8
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D.
S., et al. (2000). Antidepressant effects of ketamine in depressed patients. Biol.
Psychiatry 47, 351–354. doi: 10.1016/S0006-3223(99)00230-9
Beurel, E., Grieco, S. F., and Jope, R. S. (2015). Glycogen synthase kinase-3
(GSK3): regulation, actions, and diseases. Pharmacol. Ther. 148, 114–131. doi:
10.1016/j.pharmthera.2014.11.016
Beurel, E., Song, L., and Jope, R. S. (2011). Inhibition of glycogen synthase kinase-
3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol.
Psychiatry 16, 1068–1070. doi: 10.1038/mp.2011.47
Burgdorf, J., Zhang, X. L., Nicholson, K. L., Balster, R. L., Leander, J. D., Stanton,
P. K., et al. (2013). GLYX-13, a NMDA receptor glycine-site functional partial
agonist, induces antidepressant-like effects without ketamine-like side effects.
Neuropsychopharmacology 38, 729–742. doi: 10.1038/npp.2012.246
Carrier, N., and Kabbaj, M. (2013). Sex differences in the antidepressant-
like effects of ketamine. Neuropharmacology 70, 27–34. doi:
10.1016/j.neuropharm.2012.12.009
Chalecka-Franaszek, E., and Chuang, D. M. (1999). Lithium activates the
serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of
Akt-1 activity in neurons. Proc. Natl. Acad. Sci. U.S.A. 96, 8745–8750. doi:
10.1073/pnas.96.15.8745
Chiu, C. T., Scheuing, L., Liu, G., Liao, H. M., Linares, G. R., Lin, D., et al.
(2014). The mood stabilizer lithium potentiates the antidepressant-like effects
and ameliorates oxidative stress induced by acute ketamine in a mouse model
of stress. Int. J. Neuropsychopharmacol. 18:pyu102. doi: 10.1093/ijnp/pyu102
Cipriani, A., Pretty, H., Hawton, K., and Geddes, J. R. (2005). Lithium in the
prevention of suicidal behavior and all-cause mortality in patients with mood
disorders: a systematic review of randomized trials. Am. J. Psychiatry 162,
1805–1819. doi: 10.1176/appi.ajp.162.10.1805
Collaborators, U. S. B. O. D. (2013). The state of US health, 1990-2010:
burden of diseases, injuries, and risk factors. JAMA 310, 591–608. doi:
10.1001/jama.2013.13805
Cross, D. A., Alessi, D. R., Cohen, P., Andjelkovich, M., and Hemmings, B. A.
(1995). Inhibition of glycogen synthase kinase-3 by insulin mediated by protein
kinase B. Nature 378, 785–789. doi: 10.1038/378785a0
Da Silva, F. C., Do Carmo De Oliveira Cito, M., Da Silva, M. I., Moura, B. A., De
Aquino Neto, M. R., Feitosa, M. L., et al. (2010). Behavioral alterations and pro-
oxidant effect of a single ketamine administration to mice. Brain Res. Bull. 83,
9–15. doi: 10.1016/j.brainresbull.2010.05.011
De Oliveira, L., Spiazzi, C. M., Bortolin, T., Canever, L., Petronilho, F., Mina, F.
G., et al. (2009). Different sub-anesthetic doses of ketamine increase oxidative
stress in the brain of rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 33,
1003–1008. doi: 10.1016/j.pnpbp.2009.05.010
Diazgranados, N., Ibrahim, L., Brutsche, N. E., Newberg, A., Kronstein, P., Khalife,
S., et al. (2010). A randomized add-on trial of an N-methyl-D-aspartate
antagonist in treatment-resistant bipolar depression. Arch. Gen. Psychiatry 67,
793–802. doi: 10.1001/archgenpsychiatry.2010.90
Egan, M. F., Kojima, M., Callicott, J. H., Goldberg, T. E., Kolachana, B. S.,
Bertolino, A., et al. (2003). The BDNF val66met polymorphism affects activity-
dependent secretion of BDNF and human memory and hippocampal function.
Cell 112, 257–269. doi: 10.1016/S0092-8674(03)00035-7
Feder, A., Parides, M. K., Murrough, J. W., Perez, A. M., Morgan, J. E., Saxena,
S., et al. (2014). Efficacy of intravenous ketamine for treatment of chronic
posttraumatic stress disorder: a randomized clinical trial. JAMA Psychiatry 71,
681–688. doi: 10.1001/jamapsychiatry.2014.62
Fenton, T. R., and Gout, I. T. (2011). Functions and regulation of the
70kDa ribosomal S6 kinases. Int. J. Biochem. Cell Biol. 43, 47–59. doi:
10.1016/j.biocel.2010.09.018
Feyissa, A. M., Chandran, A., Stockmeier, C. A., and Karolewicz, B. (2009).
Reduced levels of NR2A and NR2B subunits of NMDA receptor and PSD-95 in
the prefrontal cortex in major depression. Prog. Neuropsychopharmacol. Biol.
Psychiatry 33, 70–75. doi: 10.1016/j.pnpbp.2008.10.005
Freland, L., and Beaulieu, J. M. (2012). Inhibition of GSK3 by lithium, from
single molecules to signaling networks. Front. Mol. Neurosci. 5:14. doi:
10.3389/fnmol.2012.00014
Gao, Y., Romero-Aleshire, M. J., Cai, Q., Price, T. J., and Brooks, H. L. (2013).
Rapamycin inhibition of mTORC1 reverses lithium-induced proliferation of
renal collecting duct cells. Am. J. Physiol. Renal Physiol. 305, F1201–1208. doi:
10.1152/ajprenal.00153.2013
Garcia, L. S., Comim, C. M., Valvassori, S. S., Reus, G. Z., Barbosa, L. M.,
Andreazza, A. C., et al. (2008). Acute administration of ketamine induces
antidepressant-like effects in the forced swimming test and increases BDNF
levels in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiatry 32,
140–144. doi: 10.1016/j.pnpbp.2007.07.027
Gingras, A. C., Raught, B., Gygi, S. P., Niedzwiecka, A., Miron, M., Burley, S. K.,
et al. (2001). Hierarchical phosphorylation of the translation inhibitor 4E-BP1.
Genes Dev. 15, 2852–2864. doi: 10.1101/gad.912401
Gunduz-Bruce, H. (2009). The acute effects of NMDA antagonism: from
the rodent to the human brain. Brain Res. Rev. 60, 279–286. doi:
10.1016/j.brainresrev.2008.07.006
Hashimoto, R., Fujimaki, K., Jeong, M. R., Christ, L., and Chuang, D. M.
(2003). Lithium-induced inhibition of Src tyrosine kinase in rat cerebral
cortical neurons: a role in neuroprotection against N-methyl-D-aspartate
receptor-mediated excitotoxicity. FEBS Lett. 538, 145–148. doi: 10.1016/S0014-
5793(03)00167-4
Hashimoto, R., Hough, C., Nakazawa, T., Yamamoto, T., and Chuang, D. M.
(2002). Lithium protection against glutamate excitotoxicity in rat cerebral
cortical neurons: involvement of NMDA receptor inhibition possibly by
decreasing NR2B tyrosine phosphorylation. J. Neurochem. 80, 589–597. doi:
10.1046/j.0022-3042.2001.00728.x
Insel, T. R., andWang, P. S. (2009). The STAR*D trial: revealing the need for better
treatments. Psychiatr. Serv. 60, 1466–1467. doi: 10.1176/ps.2009.60.11.1466
Jernigan, C. S., Goswami, D. B., Austin, M. C., Iyo, A. H., Chandran,
A., Stockmeier, C. A., et al. (2011). The mTOR signaling pathway in
the prefrontal cortex is compromised in major depressive disorder.
Prog. Neuropsychopharmacol. Biol. Psychiatry 35, 1774–1779. doi:
10.1016/j.pnpbp.2011.05.010
Kavalali, E. T., and Monteggia, L. M. (2012). Synaptic mechanisms underlying
rapid antidepressant action of ketamine. Am. J. Psychiatry 169, 1150–1156. doi:
10.1176/appi.ajp.2012.12040531
Kim, D. H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-
Bromage, H., et al. (2002). mTOR interacts with raptor to form a nutrient-
sensitive complex that signals to the cell growth machinery. Cell 110, 163–175.
doi: 10.1016/S0092-8674(02)00808-5
Krystal, J. H., D’souza, D. C., Mathalon, D., Perry, E., Belger, A., and Hoffman,
R. (2003). NMDA receptor antagonist effects, cortical glutamatergic function,
and schizophrenia: toward a paradigm shift in medication development.
Psychopharmacol. (Berl). 169, 215–233. doi: 10.1007/s00213-003-1582-z
Krystal, J. H., Perry, E. B. Jr., Gueorguieva, R., Belger, A., Madonick, S.
H., Abi-Dargham, A., et al. (2005). Comparative and interactive human
psychopharmacologic effects of ketamine and amphetamine: implications for
glutamatergic and dopaminergicmodel psychoses and cognitive function.Arch.
Gen. Psychiatry 62, 985–994. doi: 10.1001/archpsyc.62.9.985
Laje, G., Lally, N., Mathews, D., Brutsche, N., Chemerinski, A., Akula, N.,
et al. (2012). Brain-derived neurotrophic factor Val66Met polymorphism and
antidepressant efficacy of ketamine in depressed patients. Biol. Psychiatry 72,
e27–e28. doi: 10.1016/j.biopsych.2012.05.031
Lally, N., Nugent, A. C., Luckenbaugh, D. A., Ameli, R., Roiser, J. P., and Zarate,
C. A. (2014). Anti-anhedonic effect of ketamine and its neural correlates
in treatment-resistant bipolar depression. Transl. Psychiatry 4, e469. doi:
10.1038/tp.2014.105
Frontiers in Neuroscience | www.frontiersin.org 6 July 2015 | Volume 9 | Article 249
Scheuing et al. Ketamine’s antidepressant mechanism of action
Lepack, A. E., Fuchikami, M., Dwyer, J. M., Banasr, M., and Duman, R. S.
(2014). BDNF release is required for the behavioral actions of ketamine. Int.
J. Neuropsychopharmacol. 18:pyu033. doi: 10.1093/ijnp/pyu033
Li, N., Lee, B., Liu, R. J., Banasr, M., Dwyer, J. M., Iwata, M., et al. (2010).
mTOR-dependent synapse formation underlies the rapid antidepressant effects
of NMDA antagonists. Science 329, 959–964. doi: 10.1126/science.1190287
Li, N., Liu, R. J., Dwyer, J. M., Banasr, M., Lee, B., Son, H., et al. (2011). Glutamate
N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and
synaptic deficits caused by chronic stress exposure. Biol. Psychiatry 69, 754–761.
doi: 10.1016/j.biopsych.2010.12.015
Liu, R. J., Fuchikami, M., Dwyer, J. M., Lepack, A. E., Duman, R. S., and
Aghajanian, G. K. (2013). GSK-3 inhibition potentiates the synaptogenic
and antidepressant-like effects of subthreshold doses of ketamine.
Neuropsychopharmacology 38, 2268–2277. doi: 10.1038/npp.2013.128
Liu, R. J., Lee, F. S., Li, X. Y., Bambico, F., Duman, R. S., and Aghajanian, G. K.
(2012). Brain-derived neurotrophic factor Val66Met allele impairs basal and
ketamine-stimulated synaptogenesis in prefrontal cortex. Biol. Psychiatry 71,
996–1005. doi: 10.1016/j.biopsych.2011.09.030
Maeng, S., Zarate, C. A. Jr., Du, J., Schloesser, R. J., Mccammon, J., Chen, G., et al.
(2008). Cellular mechanisms underlying the antidepressant effects of ketamine:
role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.
Biol. Psychiatry 63, 349–352. doi: 10.1016/j.biopsych.2007.05.028
Monteggia, L. M., and Zarate, C. Jr. (2015). Antidepressant actions of ketamine:
from molecular mechanisms to clinical practice. Curr. Opin. Neurobiol. 30,
139–143. doi: 10.1016/j.conb.2014.12.004
Murray, C. J., Vos, T., Lozano, R., Naghavi, M., Flaxman, A. D., Michaud, C., et al.
(2012). Disability-adjusted life years (DALYs) for 291 diseases and injuries in
21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease
Study 2010. Lancet 380, 2197–2223. doi: 10.1016/S0140-6736(12)61689-4
Murrough, J. W., Iosifescu, D. V., Chang, L. C., Al Jurdi, R. K., Green, C. E., Perez,
A. M., et al. (2013a). Antidepressant efficacy of ketamine in treatment-resistant
major depression: a two-site randomized controlled trial. Am. J. Psychiatry 170,
1134–1142. doi: 10.1176/appi.ajp.2013.13030392
Murrough, J. W., Perez, A. M., Pillemer, S., Stern, J., Parides, M. K., Aan Het Rot,
M., et al. (2013b). Rapid and longer-term antidepressant effects of repeated
ketamine infusions in treatment-resistant major depression. Biol. Psychiatry 74,
250–256. doi: 10.1016/j.biopsych.2012.06.022
Ng, F., Berk, M., Dean, O., and Bush, A. I. (2008). Oxidative stress in
psychiatric disorders: evidence base and therapeutic implications. Int. J.
Neuropsychopharmacol. 11, 851–876. doi: 10.1017/S1461145707008401
Nosyreva, E., Szabla, K., Autry, A. E., Ryazanov, A. G., Monteggia, L.
M., and Kavalali, E. T. (2013). Acute suppression of spontaneous
neurotransmission drives synaptic potentiation. J. Neurosci. 33, 6990–7002.
doi: 10.1523/JNEUROSCI.4998-12.2013
Park, S. W., Lee, J. G., Seo, M. K., Lee, C. H., Cho, H. Y., Lee, B. J., et al.
(2014). Differential effects of antidepressant drugs on mTOR signalling in
rat hippocampal neurons. Int. J. Neuropsychopharmacol. 17, 1831–1846. doi:
10.1017/S1461145714000534
Petryshen, T. L., Sabeti, P. C., Aldinger, K. A., Fry, B., Fan, J. B., Schaffner, S. F.,
et al. (2010). Population genetic study of the brain-derived neurotrophic factor
(BDNF) gene.Mol. Psychiatry 15, 810–815. doi: 10.1038/mp.2009.24
Popik, P., Kos, T., Sowa-Kucma, M., and Nowak, G. (2008). Lack of persistent
effects of ketamine in rodent models of depression. Psychopharmacol. (Berl).
198, 421–430. doi: 10.1007/s00213-008-1158-z
Price, R. B., Iosifescu, D. V., Murrough, J. W., Chang, L. C., Al Jurdi, R. K., Iqbal, S.
Z., et al. (2014). Effects of ketamine on explicit and implicit suicidal cognition: a
randomized controlled trial in treatment-resistant depression.Depress. Anxiety
31, 335–343. doi: 10.1002/da.22253
Price, R. B., Nock, M. K., Charney, D. S., and Mathew, S. J. (2009).
Effects of intravenous ketamine on explicit and implicit measures of
suicidality in treatment-resistant depression. Biol. Psychiatry 66, 522–526. doi:
10.1016/j.biopsych.2009.04.029
Rapoport, S. I. (2014). Lithium and the other mood stabilizers effective in bipolar
disorder target the rat brain arachidonic acid cascade. ACS Chem. Neurosci. 5,
459–467. doi: 10.1021/cn500058v
Rodriguez, C. I., Kegeles, L. S., Levinson, A., Feng, T., Marcus, S. M., Vermes,
D., et al. (2013). Randomized controlled crossover trial of ketamine in
obsessive-compulsive disorder: proof-of-concept. Neuropsychopharmacology
38, 2475–2483. doi: 10.1038/npp.2013.150
Sanacora, G., and Schatzberg, A. F. (2015). Ketamine: promising path or
false prophecy in the development of novel therapeutics for mood
disorders? Neuropsychopharmacology 40, 1307. doi: 10.1038/npp.
2014.338
Sarandol, A., Sarandol, E., Eker, S. S., Erdinc, S., Vatansever, E., and Kirli, S. (2007).
Major depressive disorder is accompanied with oxidative stress: short-term
antidepressant treatment does not alter oxidative-antioxidative systems. Hum.
Psychopharmacol. 22, 67–73. doi: 10.1002/hup.829
Sarbassov, D. D., Ali, S. M., Kim, D. H., Guertin, D. A., Latek, R. R.,
Erdjument-Bromage, H., et al. (2004). Rictor, a novel binding partner of
mTOR, defines a rapamycin-insensitive and raptor-independent pathway that
regulates the cytoskeleton. Curr. Biol. 14, 1296–1302. doi: 10.1016/j.cub.2004.
06.054
Sarbassov, D. D., Ali, S. M., and Sabatini, D. M. (2005). Growing roles
for the mTOR pathway. Curr. Opin. Cell Biol. 17, 596–603. doi:
10.1016/j.ceb.2005.09.009
Sutherland, C., Leighton, I. A., and Cohen, P. (1993). Inactivation of glycogen
synthase kinase-3 beta by phosphorylation: new kinase connections in insulin
and growth-factor signalling. Biochem. J. 296(Pt 1), 15–19.
Trullas, R., and Skolnick, P. (1990). Functional antagonists at the NMDA receptor
complex exhibit antidepressant actions. Eur. J. Pharmacol. 185, 1–10. doi:
10.1016/0014-2999(90)90204-J
Yasuda, S., Liang, M. H., Marinova, Z., Yahyavi, A., and Chuang, D. M. (2009). The
mood stabilizers lithium and valproate selectively activate the promoter IV of
brain-derived neurotrophic factor in neurons. Mol. Psychiatry 14, 51–59. doi:
10.1038/sj.mp.4002099
Yilmaz, A., Schulz, D., Aksoy, A., and Canbeyli, R. (2002). Prolonged effect of an
anesthetic dose of ketamine on behavioral despair. Pharmacol. Biochem. Behav.
71, 341–344. doi: 10.1016/S0091-3057(01)00693-1
Zarate, C. A. Jr., Brutsche, N. E., Ibrahim, L., Franco-Chaves, J., Diazgranados, N.,
Cravchik, A., et al. (2012b). Replication of ketamine’s antidepressant efficacy in
bipolar depression: a randomized controlled add-on trial. Biol. Psychiatry 71,
939–946. doi: 10.1016/j.biopsych.2011.12.010
Zarate, C. A. Jr., Brutsche, N., Laje, G., Luckenbaugh, D. A., Venkata, S. L.,
Ramamoorthy, A., et al. (2012a). Relationship of ketamine’s plasma metabolites
with response, diagnosis, and side effects in major depression. Biol. Psychiatry
72, 331–338. doi: 10.1016/j.biopsych.2012.03.004
Zarate, C. A. Jr., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh,
D. A., et al. (2006). A randomized trial of an N-methyl-D-aspartate antagonist
in treatment-resistant major depression.Arch. Gen. Psychiatry 63, 856–864. doi:
10.1001/archpsyc.63.8.856
Zunszain, P. A., Horowitz, M. A., Cattaneo, A., Lupi, M. M., and Pariante,
C. M. (2013). Ketamine: synaptogenesis, immunomodulation and glycogen
synthase kinase-3 as underlying mechanisms of its antidepressant properties.
Mol. Psychiatry 18, 1236–1241. doi: 10.1038/mp.2013.87
Zuo, D. Y., Wu, Y. L., Yao, W. X., Cao, Y., Wu, C. F., and Tanaka, M.
(2007). Effect of MK-801 and ketamine on hydroxyl radical generation in
the posterior cingulate and retrosplenial cortex of free-moving mice, as
determined by in vivo microdialysis. Pharmacol. Biochem. Behav. 86, 1–7. doi:
10.1016/j.pbb.2006.05.010
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2015 Scheuing, Chiu, Liao and Chuang. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Neuroscience | www.frontiersin.org 7 July 2015 | Volume 9 | Article 249
